ImmunityBio $10.5M Securities Class Action Settlement

If you purchased or acquired ImmunityBio, Inc. (NASDAQ: IBRX) securities between March 10, 2021, and May 10, 2023, inclusive, and suffered financial losses as a result, you may be eligible to submit a claim for a payment from a $10.5 million class action settlement.

ImmunityBio, Inc. has agreed to pay $10,500,000 to settle allegations that the company and certain executives violated U.S. federal securities laws. The class action lawsuit claimed that ImmunityBio made materially misleading statements and omissions regarding its manufacturing capabilities, compliance with FDA regulations, and the prospects for FDA approval of its lead product candidate, Anktiva.

Who is eligible for a settlement payout?

You are a class member if you purchased or acquired ImmunityBio securities (NASDAQ: IBRX) between March 10, 2021, and May 10, 2023, inclusive.

How much will my class action payment be?

Pro Rata Cash Payment: After deducting fees and expenses from the settlement fund, the average recovery is estimated at approximately $0.09 per damaged share. Payment amount will be determined by multiple factors:

• The number of valid claims submitted
• The number of shares you purchased or acquired
• The dates and prices of your transactions
• Recognized Loss according to the Plan of Allocation

How to claim a class action settlement payout

To receive a stockholder payment, class members must submit a claim form by the deadline of July 7, 2025. You can file a claim online or print and complete the PDF claim form and mail it to the settlement administrator.

Settlement Administrator's mailing address: ImmunityBio Securities Settlement c/o Epiq, PO Box 2239, Portland, OR 97208-2239

Is proof required to submit a claim?

Yes, supporting documentation is required. Claimants must include copies of brokerage confirmations, monthly statements, or other official records detailing your ImmunityBio transactions.

Payment options

All approved claimants will receive a paper check mailed to the address provided.

$10.5 Million class action settlement fund

The settlement fund of $10,500,000 will include:

• Settlement administration costs: Up to $350,000
• Attorneys' fees: Up to $3,500,000
• Attorneys' expenses: Up to $200,000
• Service award to lead plaintiff: Up to $15,000
• Payments to class members with valid claims: Remaining settlement funds

Important dates

• Fairness Hearing: June 13, 2025
• Deadline to File a Claim: July 7, 2025

When is the ImmunityBio securities class action settlement payout date?

Payments will be issued to approved claimants after the court grants final approval and the claim deadline has passed. The fairness hearing will take place on June 13, 2025.

Why was ImmunityBio sued?

The class action lawsuit alleged that ImmunityBio and its executives violated federal securities laws by making materially false and misleading statements about the company's manufacturing capabilities, compliance with FDA regulations, and the likelihood of FDA approval for its lead product candidate, Anktiva. The lawsuit claimed these misrepresentations led to investor losses.

ImmunityBio denies these allegations but agreed to settle to avoid the risks of continued litigation and the possibility of a trial.

Sources

1. Official Settlement Notice
2. Settlement Website FAQ Page
3. ImmunityBio Securities Settlement Website